Hepatology Research

Papers
(The H4-Index of Hepatology Research is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”282
Deceased Donation Disparities in East Asia—A Tale of Two Systems60
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ45
Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study44
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan39
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation35
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis34
Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study33
Efficacy and Safety of Direct Oral Anticoagulants in Budd–Chiari Syndrome After Percutaneous Recanalization32
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome28
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma27
Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy26
Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan24
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs24
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?23
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval23
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases23
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study22
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase22
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol22
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he21
Acknowledgment21
0.16695094108582